JP2023504209A5 - - Google Patents
Info
- Publication number
- JP2023504209A5 JP2023504209A5 JP2022534708A JP2022534708A JP2023504209A5 JP 2023504209 A5 JP2023504209 A5 JP 2023504209A5 JP 2022534708 A JP2022534708 A JP 2022534708A JP 2022534708 A JP2022534708 A JP 2022534708A JP 2023504209 A5 JP2023504209 A5 JP 2023504209A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- antibody
- subject
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025032847A JP2025084932A (ja) | 2019-12-09 | 2025-03-03 | 視神経脊髄炎スペクトラム障害の治療のための抗c5抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945644P | 2019-12-09 | 2019-12-09 | |
| US62/945,644 | 2019-12-09 | ||
| PCT/US2020/063781 WO2021118999A1 (en) | 2019-12-09 | 2020-12-08 | Anti-c5 antibody for the treatment of neuromyelitis optica spectrum disorder |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025032847A Division JP2025084932A (ja) | 2019-12-09 | 2025-03-03 | 視神経脊髄炎スペクトラム障害の治療のための抗c5抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023504209A JP2023504209A (ja) | 2023-02-01 |
| JP2023504209A5 true JP2023504209A5 (cg-RX-API-DMAC10.html) | 2023-12-22 |
| JP7789672B2 JP7789672B2 (ja) | 2025-12-22 |
Family
ID=74046204
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022534708A Active JP7789672B2 (ja) | 2019-12-09 | 2020-12-08 | 視神経脊髄炎スペクトラム障害の治療のための抗c5抗体 |
| JP2025032847A Pending JP2025084932A (ja) | 2019-12-09 | 2025-03-03 | 視神経脊髄炎スペクトラム障害の治療のための抗c5抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025032847A Pending JP2025084932A (ja) | 2019-12-09 | 2025-03-03 | 視神経脊髄炎スペクトラム障害の治療のための抗c5抗体 |
Country Status (11)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260022164A1 (en) * | 2022-05-04 | 2026-01-22 | Alexion Pharmaceuticals, Inc. | Compositions and methods for the treatment of neuromyelitis optica spectrum disorder |
| WO2025221479A1 (en) * | 2024-04-16 | 2025-10-23 | Alexion Pharmaceuticals, Inc. | Biomarkers for monitoring effective treatment of neuromyelitis optica spectrum disorder (nmosd) with complement component c5 inhibitors |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5135916A (en) | 1989-06-12 | 1992-08-04 | Oklahoma Medical Research Foundation | Inhibition of complement mediated inflammatory response |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| HUE066795T2 (hu) | 2006-03-15 | 2024-09-28 | Alexion Pharma Inc | Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| JP6223659B2 (ja) | 2008-11-10 | 2017-11-01 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 補体関連障害を処置するための方法および組成物 |
| JO3437B1 (ar) * | 2009-10-30 | 2019-10-20 | Esai R & D Man Co Ltd | أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها |
| AU2011245117B2 (en) * | 2010-04-30 | 2015-03-12 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies and methods for using the antibodies |
| CA2798120A1 (en) | 2010-04-30 | 2011-11-03 | Paul P. Tamburini | Antibodies having reduced immunogenicity in a human |
| TW201241008A (en) * | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
| PT2970974T (pt) | 2013-03-14 | 2017-11-29 | Alnylam Pharmaceuticals Inc | Composições de irna de componente do complemento c5 e métodos para a sua utilização |
| AU2014306002B2 (en) | 2013-08-07 | 2017-05-25 | Alexion Pharmaceuticals, Inc. | Atypical hemolytic uremic syndrome (aHUS) biomarker proteins |
| NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| EA201791366A1 (ru) | 2014-12-19 | 2018-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к c5 и способы их применения |
| WO2016209956A1 (en) * | 2015-06-26 | 2016-12-29 | Alexion Pharmaceuticals, Inc. | A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant |
| US20190023775A1 (en) | 2016-01-11 | 2019-01-24 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
| IL263481B2 (en) | 2016-06-14 | 2024-06-01 | Regeneron Pharma | Anti-c5 antibodies and uses thereof |
| WO2018183449A1 (en) * | 2017-03-31 | 2018-10-04 | Alexion Pharmaceuticals, Inc. | Method for simultaneous quantification of alxn1210 and eculizumab in human serum or urine |
| US20200095307A1 (en) | 2018-09-21 | 2020-03-26 | Alexion Pharmaceuticals, Inc. | Compositions and methods for the treatment of neuromyelitis optica |
| US20230416344A1 (en) | 2020-04-16 | 2023-12-28 | Alexion Pharmaceuticals, Inc. | Methods for treating a complement mediated disorder caused by viruses |
| CA3193488A1 (en) | 2020-09-23 | 2022-03-31 | Jason Allan Wiles | Pharmaceutical compounds for the treatment of complement mediated disorders |
| US20260022164A1 (en) | 2022-05-04 | 2026-01-22 | Alexion Pharmaceuticals, Inc. | Compositions and methods for the treatment of neuromyelitis optica spectrum disorder |
| WO2025221479A1 (en) | 2024-04-16 | 2025-10-23 | Alexion Pharmaceuticals, Inc. | Biomarkers for monitoring effective treatment of neuromyelitis optica spectrum disorder (nmosd) with complement component c5 inhibitors |
-
2020
- 2020-12-08 CA CA3161271A patent/CA3161271A1/en active Pending
- 2020-12-08 JP JP2022534708A patent/JP7789672B2/ja active Active
- 2020-12-08 AU AU2020401102A patent/AU2020401102A1/en active Pending
- 2020-12-08 MX MX2022007116A patent/MX2022007116A/es unknown
- 2020-12-08 CN CN202411616594.9A patent/CN119548622A/zh active Pending
- 2020-12-08 US US17/783,106 patent/US12612451B2/en active Active
- 2020-12-08 CN CN202080085425.0A patent/CN114867747A/zh active Pending
- 2020-12-08 EP EP20829482.7A patent/EP4073110A1/en active Pending
- 2020-12-08 WO PCT/US2020/063781 patent/WO2021118999A1/en not_active Ceased
- 2020-12-08 BR BR112022011280A patent/BR112022011280A2/pt unknown
- 2020-12-08 KR KR1020227023328A patent/KR20220110827A/ko active Pending
-
2022
- 2022-07-01 CO CONC2022/0009246A patent/CO2022009246A2/es unknown
-
2025
- 2025-03-03 JP JP2025032847A patent/JP2025084932A/ja active Pending